☰

Monica Venere, Ph.D. - Publications

Affiliations: 
2005 University of Pennsylvania, Philadelphia, PA, United States 
Area:
Cell Biology, Molecular Biology
Tree Info Similar researchers PubMed Report error

27 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Summers MK, Venere M. Walking the tightrope between DNA damage repair and genomic integrity. Neuro-Oncology. PMID 37963038 DOI: 10.1093/neuonc/noad218  0.374
2021 Venere M, Lathia JD. All Damage Is Not Created Equal: Unraveling the Complexity of Sex Chromosomes and Hormones in the DNA Damage Response. Endocrinology. 162. PMID 34618897 DOI: 10.1210/endocr/bqab213  0.354
2020 Zalenski AA, Majumder S, De K, Venere M. An interphase pool of KIF11 localizes at the basal bodies of primary cilia and a reduction in KIF11 expression alters cilia dynamics. Scientific Reports. 10: 13946. PMID 32811879 DOI: 10.1038/S41598-020-70787-4  0.344
2020 Pal D, Torres AE, Stromberg BR, Messina AL, Dickson AS, De K, Willard B, Venere M, Summers MK. Chk1-mediated phosphorylation of Cdh1 promotes the SCF-dependent degradation of Cdh1 during S-phase and efficient cell-cycle progression. Cell Death & Disease. 11: 298. PMID 32345958 DOI: 10.1038/S41419-020-2493-1  0.462
2019 De K, Grubb TM, Zalenski AA, Pfaff KE, Pal D, Majumder S, Summers MK, Venere M. Hyperphosphorylation of CDH1 in glioblastoma cancer stem cells attenuates APC/CCDH1 activity and pharmacological inhibition of APC/CCDH1/CDC20 compromises viability. Molecular Cancer Research : McR. PMID 31036696 DOI: 10.1158/1541-7786.Mcr-18-1361  0.331
2018 Jarrar A, Lotti F, DeVecchio J, Ferrandon S, Gantt G, Mace A, Karagkounis G, Orloff M, Venere M, Hitomi M, Lathia J, Rich JN, Kalady MF. PARP inhibition sensitizes colorectal cancer-initiating cells to chemotherapy. Stem Cells (Dayton, Ohio). PMID 30353615 DOI: 10.1002/Stem.2929  0.438
2018 Sharma A, Alswillah T, Singh K, Chatterjee P, Willard B, Venere M, Summers MK, Almasan A. USP14 regulates DNA damage repair by targeting RNF168-dependent ubiquitination. Autophagy. PMID 29995557 DOI: 10.1080/15548627.2018.1496877  0.603
2017 Venere M. Self-tanning cells, the new SPF. Science Translational Medicine. 9. PMID 28679660 DOI: 10.1126/Scitranslmed.Aan8202  0.322
2016 Dermawan JK, Hitomi M, Silver DJ, Wu Q, Sandlesh P, Sloan AE, Purmal AA, Gurova KV, Rich JN, Lathia JD, Stark GR, Venere M. Pharmacological targeting of the histone chaperone complex FACT preferentially eliminates glioblastoma stem cells and prolongs survival in preclinical models. Cancer Research. PMID 26921329 DOI: 10.1158/0008-5472.Can-15-2162  0.301
2014 Venere M, Hamerlik P, Wu Q, Rasmussen RD, Song LA, Vasanji A, Tenley N, Flavahan WA, Hjelmeland AB, Bartek J, Rich JN. Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells. Cell Death and Differentiation. 21: 258-69. PMID 24121277 DOI: 10.1038/Cdd.2013.136  0.531
2014 Venere M, Crish J, Wu Q, Horbinski C, Rich J, Rosenfeld S. SC-32 * TARGETING PROLIFERATION AND INVASION IN GLIOBLASTOMA VIA MITOTIC KINESINS Neuro-Oncology. 16: v203-v204. DOI: 10.1093/Neuonc/Nou275.31  0.303
2013 Date DA, Burrows AC, Venere M, Jackson MW, Summers MK. Coordinated regulation of p31(Comet) and Mad2 expression is required for cellular proliferation. Cell Cycle (Georgetown, Tex.). 12: 3824-32. PMID 24131926 DOI: 10.4161/Cc.26811  0.363
2013 Schonberg DL, Venere M, Rich JN. Changing the fate of cancer, one splice at a time. Proceedings of the National Academy of Sciences of the United States of America. 110: 14510-1. PMID 23969832 DOI: 10.1073/Pnas.1313419110  0.31
2013 Venere M, Lathia JD, Rich JN. Growth factor receptors define cancer hierarchies. Cancer Cell. 23: 135-7. PMID 23410969 DOI: 10.1016/J.Ccr.2013.01.020  0.342
2010 Mayers CM, Wadell J, McLean K, Venere M, Malik M, Shibata T, Driggers PH, Kino T, Guo XC, Koide H, Gorivodsky M, Grinberg A, Mukhopadhyay M, Abu-Asab M, Westphal H, et al. The Rho guanine nucleotide exchange factor AKAP13 (BRX) is essential for cardiac development in mice. The Journal of Biological Chemistry. 285: 12344-54. PMID 20139090 DOI: 10.1074/Jbc.M110.106856  0.366
2007 Venere M, Snyder A, Zgheib O, Halazonetis TD. Phosphorylation of ATR-interacting protein on Ser239 mediates an interaction with breast-ovarian cancer susceptibility 1 and checkpoint function. Cancer Research. 67: 6100-5. PMID 17616665 DOI: 10.1158/0008-5472.Can-07-0369  0.804
2007 Tsimaratou K, Kletsas D, Kastrinakis NG, Tsantoulis PK, Evangelou K, Sideridou M, Liontos M, Poulias I, Venere M, Salmas M, Kittas C, Halazonetis TD, Gorgoulis VG. Evaluation of claspin as a proliferation marker in human cancer and normal tissues. The Journal of Pathology. 211: 331-9. PMID 17152083 DOI: 10.1002/Path.2095  0.641
2006 Peschiaroli A, Dorrello NV, Guardavaccaro D, Venere M, Halazonetis T, Sherman NE, Pagano M. SCFbetaTrCP-mediated degradation of Claspin regulates recovery from the DNA replication checkpoint response. Molecular Cell. 23: 319-29. PMID 16885022 DOI: 10.1016/J.Molcel.2006.06.013  0.759
2005 Livingstone M, Ruan H, Weiner J, Clauser KR, Strack P, Jin S, Williams A, Greulich H, Gardner J, Venere M, Mochan TA, DiTullio RA, Moravcevic K, Gorgoulis VG, Burkhardt A, et al. Valosin-containing protein phosphorylation at Ser784 in response to DNA damage. Cancer Research. 65: 7533-40. PMID 16140914 DOI: 10.1158/0008-5472.Can-04-3729  0.792
2005 Zgheib O, Huyen Y, DiTullio RA, Snyder A, Venere M, Stavridi ES, Halazonetis TD. ATM signaling and 53BP1. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 76: 119-22. PMID 16024119 DOI: 10.1016/J.Radonc.2005.06.026  0.78
2005 Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio RA, Kastrinakis NG, Levy B, Kletsas D, Yoneta A, Herlyn M, Kittas C, Halazonetis TD. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature. 434: 907-13. PMID 15829965 DOI: 10.1038/Nature03485  0.827
2004 MacPherson D, Kim J, Kim T, Rhee BK, Van Oostrom CT, DiTullio RA, Venere M, Halazonetis TD, Bronson R, De Vries A, Fleming M, Jacks T. Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23. The Embo Journal. 23: 3689-99. PMID 15343266 DOI: 10.1038/Sj.Emboj.7600363  0.764
2004 Mochan TA, Venere M, DiTullio RA, Halazonetis TD. 53BP1, an activator of ATM in response to DNA damage. Dna Repair. 3: 945-52. PMID 15279780 DOI: 10.1016/J.Dnarep.2004.03.017  0.794
2003 Mochan TA, Venere M, DiTullio RA, Halazonetis TD. 53BP1 and NFBD1/MDC1-Nbs1 function in parallel interacting pathways activating ataxia-telangiectasia mutated (ATM) in response to DNA damage. Cancer Research. 63: 8586-91. PMID 14695167  0.79
2003 Bothos J, Summers MK, Venere M, Scolnick DM, Halazonetis TD. The Chfr mitotic checkpoint protein functions with Ubc13-Mms2 to form Lys63-linked polyubiquitin chains. Oncogene. 22: 7101-7. PMID 14562038 DOI: 10.1038/Sj.Onc.1206831  0.753
2002 DiTullio RA, Mochan TA, Venere M, Bartkova J, Sehested M, Bartek J, Halazonetis TD. 53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer. Nature Cell Biology. 4: 998-1002. PMID 12447382 DOI: 10.1038/Ncb892  0.793
2002 Venere M, Mochan TA, Halazonetis TD. Chk2 leaves the PML depot. Nature Cell Biology. 4: E255-6. PMID 12415282 DOI: 10.1038/Ncb1102-E255  0.762
Show low-probability matches.